Cancer immunotherapy and uveitis: balancing anti-tumor immunity and ocular autoimmunity
A Rali, Y Huang, S Yeh - International ophthalmology clinics, 2022 - journals.lww.com
This project was supported by the National Eye Institute of the National Institutes of Health
under award number R01 EY029594 (SY). The content is solely the responsibility of the …
under award number R01 EY029594 (SY). The content is solely the responsibility of the …
Challenges in posterior uveitis—tips and tricks for the retina specialist
Purpose Posterior uveitis is a common chorioretinal pathology affecting all ages worldwide
and is a frequent reason for referral to the retina clinic. The spectrum of etiologies for uveitis …
and is a frequent reason for referral to the retina clinic. The spectrum of etiologies for uveitis …
Ocular inflammatory complications of treatment for metastatic melanoma
AM Philip, SD Anesi, CS Foster… - Ocular Immunology and …, 2023 - Taylor & Francis
Purpose To characterize various ocular inflammatory complications arising from metastatic
cutaneous melanoma therapies and their management. Methods Retrospective case series …
cutaneous melanoma therapies and their management. Methods Retrospective case series …
Large-vessel vasculitis possibly induced by BRAF and MEK inhibitors for BRAF V600E positive lung adenocarcinoma
K Ichikawa, S Ohno, S Kubo… - BMJ Case Reports …, 2024 - casereports.bmj.com
The combination therapy of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and
mitogen-activated protein kinase kinase (MEK) inhibitors is approved for treating patients …
mitogen-activated protein kinase kinase (MEK) inhibitors is approved for treating patients …
Bilaterale, zentral seröse Chorioretinopathie unter BRAF („B-rapidly accelerated fibrosarcoma “)-/MEK (mitogen-aktivierte Proteinkinase-Kinase)-Inhibitoren-Therapie …
C Rastoaca, T Berger, B Seitz, AD Abdin - Die Ophthalmologie, 2025 - Springer
Hintergrund Das kutane Melanom ist eine der aggressivsten Hautkrebsarten [2, 16]. In den
letzten Jahren wurden neue Chemotherapeutika entwickelt, um die progressionsfreie …
letzten Jahren wurden neue Chemotherapeutika entwickelt, um die progressionsfreie …
A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment
C Obaru, T Kimura, M Yamamura… - The Journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and
nivolumab treatment A case of melanoma complicated with uveitis induced by two types of …
nivolumab treatment A case of melanoma complicated with uveitis induced by two types of …
Okuläre Nebenwirkungen moderner onkologischer Therapie
S Thurau, G Wildner, MA Gamulescu - Die Ophthalmologie, 2023 - Springer
In den letzten Jahren haben Checkpointinhibitoren die Behandlung von zuvor
unbehandelbaren bösartigen Tumoren revolutioniert und sowohl Lebenserwartung wie …
unbehandelbaren bösartigen Tumoren revolutioniert und sowohl Lebenserwartung wie …
Üveite Neden Olan İlaçlar: Patogenez, Tanı ve Tedavi.
AM Yıldız, R Avcı, S Yılmaz - Güncel Retina Dergisi, 2023 - search.ebscohost.com
Sistemik, perioküler, intraoküler ve topikal yolla uygulanan bazı ilaçlar sonucu ortaya
çıkabilen ilaca bağlı üveit, son on yılda, çok sayıda yayında kapsamlı bir şekilde ele …
çıkabilen ilaca bağlı üveit, son on yılda, çok sayıda yayında kapsamlı bir şekilde ele …
A Case of Irreversible Optic Neuropathy Associated With Encorafenib/Binimetinib Therapy in a Patient With Metastatic Melanoma
BT Baugh, KB Digre, MD Seay… - Journal of Neuro …, 2022 - journals.lww.com
The standard of care in metastatic melanoma is treatment with mitogen-activated protein
kinase and B-Raf protein kinase inhibitors (MEKi/BRAFi). Encorafenib—BRAFi—and …
kinase and B-Raf protein kinase inhibitors (MEKi/BRAFi). Encorafenib—BRAFi—and …
[ОПИСАНИЕ][C] A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment
NP KK, C Obaru, T Kimura, M Yamamura, H Kuriyama…